AZD9272

AZD9272 is an investigational, orally bioavailable selective estrogen receptor degrader (SERD) being developed by AstraZeneca. It is designed to bind to the estrogen receptor (ER) in breast cancer cells and promote its degradation, thereby reducing ER signaling and inhibiting tumor growth.

AZD9272 is under clinical development as a potential treatment for estrogen receptor-positive (ER+) breast cancer, particularly in patients who have progressed on or are resistant to existing endocrine therapies such as aromatase inhibitors and tamoxifen. The rationale for its development stems from the observation that many ER+ breast cancers eventually develop resistance to these therapies, often through alterations in the ER itself or in downstream signaling pathways. SERDs like AZD9272 offer a distinct mechanism of action compared to other endocrine therapies by directly targeting the ER protein for degradation.

Clinical trials are evaluating AZD9272 both as a monotherapy and in combination with other anticancer agents, such as CDK4/6 inhibitors, in various stages of ER+ breast cancer. The goal of these studies is to assess the safety, tolerability, and efficacy of AZD9272 in overcoming endocrine resistance and improving outcomes for patients with ER+ breast cancer. The results of these trials will determine the future clinical utility of AZD9272 as a therapeutic option.